In patients with prediabetes and obesity, GLP-1+/- GIP receptor agonists may be beneficial (68) also in young individuals (69), and recent data indicate that large doses of semaglutide led to a higher chance of normoglycemia (70), while large doses of tirzepatide led to a lower risk of new-onset T2DM as compared to placebo (62). Here, GCG is linked to obesity disorder.